-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8

Benzinga · 01/06/2023 09:26
Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $35 to $8.